RxDoctor Payments Data

Elizabeth Youngewirth, DPM

Foot Surgery · New York, NYNPI 1669418992

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.

$2,733in general payments, 2019–2025

Across 59 payments — averaging $46.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Averitas Pharma Inc.$439
  • Smith+Nephew$413
  • Organogenesis Inc.$322
  • Nevro Corp.$249
  • Paratek Pharmaceuticals, Inc.$220
  • Amgen$202
  • plus $888 from 14 others

What the payments were for

  • Food & beverage$2,733100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,733 in reported general payments places this provider in the 75th percentile of 294 foot surgery providers in New York.

See all foot surgery providers in New York

Medicare billing

Part B allowed, 2024
$75,628
Medicare patients
130
Services billed
891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QutenzaCapsaicin/Skin Cleanser30$113,055
Doxepin Hcl154$96,262
Clobetasol Propionate137$60,312
Caspofungin Acetate100$25,129
Fluocinonide45$15,740
Chlorpromazine Hcl14$11,109
Ammonium Lactate360$7,134
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc22$6,259
Clotrimazole138$4,498
Diclofenac Sodium14$2,185
Ketoconazole47$1,913
Diclofenac Sodium ErDiclofenac Sodium22$1,672
Betamethasone Dipropionate20$1,324
Mupirocin156$973
Nystatin27$921

Paid to pharmacies, not to this prescriber.

Other foot surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →